ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

Researchers Discover Bacteria Common in Colon Cancer Tissue

October 28, 2011

Letter to the Editors: Society of Toxicology Comments On President’s Cancer Panel Report

August 6, 2010

NCI Programs: Study Finds Bomb Tests Raised I-131 Exposure in 1950’s, 1960’s

August 22, 1997

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

NAB Report To President Makes Pitch for Money, Cites Research Progress

August 9, 1974

NCCS Networker Volume 2 Issue 2, Spring 1988

April 13, 1988